vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and HYSTER-YALE, INC. (HY). Click either name above to swap in a different company.

HYSTER-YALE, INC. is the larger business by last-quarter revenue ($923.2M vs $749.2M, roughly 1.2× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — 3.6% vs -5.7%, a 9.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -13.5%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -6.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Hyster-Yale Materials Handling, Inc., through its wholly owned operating subsidiary, Hyster-Yale Group, Inc., designs, engineers, manufactures, sells and services a comprehensive line of lift trucks and aftermarket parts marketed globally primarily under the Hyster and Yale brand names. It was spun off from NACCO Industries in 2012, but had been running as a standalone company within NACCO since 2002.

CLOV vs HY — Head-to-Head

Bigger by revenue
HY
HY
1.2× larger
HY
$923.2M
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+75.6% gap
CLOV
62.0%
-13.5%
HY
Higher net margin
CLOV
CLOV
9.3% more per $
CLOV
3.6%
-5.7%
HY
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-6.5%
HY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
HY
HY
Revenue
$749.2M
$923.2M
Net Profit
$27.3M
$-52.5M
Gross Margin
14.2%
Operating Margin
3.6%
-4.0%
Net Margin
3.6%
-5.7%
Revenue YoY
62.0%
-13.5%
Net Profit YoY
-609.7%
EPS (diluted)
$0.05
$-2.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
HY
HY
Q1 26
$749.2M
Q4 25
$487.7M
$923.2M
Q3 25
$496.6M
$979.1M
Q2 25
$477.6M
$956.6M
Q1 25
$462.3M
$910.4M
Q4 24
$337.0M
$1.1B
Q3 24
$331.0M
$1.0B
Q2 24
$356.3M
$1.2B
Net Profit
CLOV
CLOV
HY
HY
Q1 26
$27.3M
Q4 25
$-49.3M
$-52.5M
Q3 25
$-24.4M
$-2.3M
Q2 25
$-10.6M
$-13.9M
Q1 25
$-1.3M
$8.6M
Q4 24
$-22.1M
$10.3M
Q3 24
$-9.2M
$17.2M
Q2 24
$7.4M
$63.3M
Gross Margin
CLOV
CLOV
HY
HY
Q1 26
Q4 25
14.2%
Q3 25
15.9%
Q2 25
17.6%
Q1 25
19.5%
Q4 24
19.4%
Q3 24
24.5%
19.0%
Q2 24
30.3%
22.2%
Operating Margin
CLOV
CLOV
HY
HY
Q1 26
3.6%
Q4 25
-10.1%
-4.0%
Q3 25
-4.9%
0.2%
Q2 25
-2.2%
-0.9%
Q1 25
-0.3%
2.3%
Q4 24
-6.4%
3.0%
Q3 24
-2.7%
3.3%
Q2 24
2.0%
8.2%
Net Margin
CLOV
CLOV
HY
HY
Q1 26
3.6%
Q4 25
-10.1%
-5.7%
Q3 25
-4.9%
-0.2%
Q2 25
-2.2%
-1.5%
Q1 25
-0.3%
0.9%
Q4 24
-6.6%
1.0%
Q3 24
-2.8%
1.7%
Q2 24
2.1%
5.4%
EPS (diluted)
CLOV
CLOV
HY
HY
Q1 26
$0.05
Q4 25
$-2.97
Q3 25
$-0.13
Q2 25
$-0.79
Q1 25
$0.48
Q4 24
$0.57
Q3 24
$0.97
Q2 24
$3.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
HY
HY
Cash + ST InvestmentsLiquidity on hand
$177.6M
Total DebtLower is stronger
$251.9M
Stockholders' EquityBook value
$339.4M
$472.0M
Total Assets
$697.7M
$2.0B
Debt / EquityLower = less leverage
0.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
HY
HY
Q1 26
$177.6M
Q4 25
$78.3M
Q3 25
Q2 25
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Total Debt
CLOV
CLOV
HY
HY
Q1 26
Q4 25
$251.9M
Q3 25
$252.2M
Q2 25
$245.2M
Q1 25
$242.6M
Q4 24
$241.9M
Q3 24
$247.4M
Q2 24
$248.5M
Stockholders' Equity
CLOV
CLOV
HY
HY
Q1 26
$339.4M
Q4 25
$308.7M
$472.0M
Q3 25
$340.9M
$536.0M
Q2 25
$344.2M
$544.7M
Q1 25
$336.1M
$510.0M
Q4 24
$341.1M
$475.1M
Q3 24
$342.2M
$529.9M
Q2 24
$324.9M
$465.7M
Total Assets
CLOV
CLOV
HY
HY
Q1 26
$697.7M
Q4 25
$541.0M
$2.0B
Q3 25
$559.7M
$2.1B
Q2 25
$575.0M
$2.1B
Q1 25
$583.7M
$2.1B
Q4 24
$580.7M
$2.0B
Q3 24
$653.0M
$2.2B
Q2 24
$674.2M
$2.1B
Debt / Equity
CLOV
CLOV
HY
HY
Q1 26
Q4 25
0.53×
Q3 25
0.47×
Q2 25
0.45×
Q1 25
0.48×
Q4 24
0.51×
Q3 24
0.47×
Q2 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
HY
HY
Operating Cash FlowLast quarter
$56.5M
Free Cash FlowOCF − Capex
$32.9M
FCF MarginFCF / Revenue
3.6%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$23.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
HY
HY
Q1 26
Q4 25
$-66.9M
$56.5M
Q3 25
$12.1M
$37.1M
Q2 25
$5.4M
$28.9M
Q1 25
$-16.3M
$-36.4M
Q4 24
$34.8M
$80.7M
Q3 24
$50.0M
$70.1M
Q2 24
$44.8M
$-2.5M
Free Cash Flow
CLOV
CLOV
HY
HY
Q1 26
Q4 25
$-69.0M
$32.9M
Q3 25
$11.4M
$22.6M
Q2 25
$4.8M
$15.1M
Q1 25
$-16.5M
$-47.0M
Q4 24
$33.3M
$62.8M
Q3 24
$49.6M
$59.9M
Q2 24
$44.4M
$-14.7M
FCF Margin
CLOV
CLOV
HY
HY
Q1 26
Q4 25
-14.1%
3.6%
Q3 25
2.3%
2.3%
Q2 25
1.0%
1.6%
Q1 25
-3.6%
-5.2%
Q4 24
9.9%
5.9%
Q3 24
15.0%
5.9%
Q2 24
12.5%
-1.3%
Capex Intensity
CLOV
CLOV
HY
HY
Q1 26
Q4 25
0.4%
2.6%
Q3 25
0.1%
1.5%
Q2 25
0.1%
1.4%
Q1 25
0.0%
1.2%
Q4 24
0.5%
1.7%
Q3 24
0.1%
1.0%
Q2 24
0.1%
1.0%
Cash Conversion
CLOV
CLOV
HY
HY
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
-4.23×
Q4 24
7.83×
Q3 24
4.08×
Q2 24
6.04×
-0.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

HY
HY

Sales Channel Through Intermediary$281.7M31%
Aftermarketsales$179.1M19%
Sales Channel Directly To Consumer$173.6M19%
EMEAHY$153.3M17%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$89.0M10%
Otherrevenue$42.4M5%

Related Comparisons